Adalvo proudly announces its recent induction into Medicines for Europe, a renowned association advancing the generic pharmaceutical sector.
As a member, Adalvo will play a pivotal role in shaping the future landscape of the industry through active participation in various influential commissions, including but not limited to, Value Added Medicine, Legal and Intellectual Property, Regulatory & Scientific Affairs, External Markets and Trade Policy, and National Associations.
"Our inclusion in Medicines for Europe showcases Adalvo's commitment to innovation and excellence, solidifying our position as a leader in the pharmaceutical industry," says Anil Okay, CEO of Adalvo. "We are eager to collaborate with industry leaders to redefine standards in healthcare through smart collaboration and strategic initiatives."
Adrian van den Hoven, Director General at Medicines for Europe, adds, "We are pleased to welcome Adalvo to our association. Their dedication to innovation perfectly aligns with our mission to optimize medications and improve patient care."
Adalvo looks forward to leveraging its membership in Medicines for Europe to drive positive change and innovation in the generic pharmaceutical sector.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 17 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Medicines For Europe
Medicines for Europe represents Europe's generic, biosimilar and value-added medicines industries. Its vision is to provide sustainable access to high-quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies are increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high-quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value-added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information, please follow us at www.medicinesforeurope.com and on Twitter @medicinesforEU.